Although specific stroke results from SURPASS-CVOT are not yet available, our study shows that untreated patients are at higher risk of stroke incidence, supporting the broader claim of tirzepatide’s vascular protective effects, which could also be expected in ASCVD populations.4 Moreover, in the SURPASS-2 trial, tirzepatide was superior to semaglutide, a selective GLP-1 receptor agonist, in reducing HbA1c and body weight.15 Here, GLP1R is linked to stroke disorder.